Neuronostics

Neuronostics is a clinical-stage medical technology company that provides a sophisticated digital biomarker platform, BioEP, designed to enhance the speed and accuracy of epilepsy diagnosis. By 2026, Neuronostics has solidified its position as a critical layer in neurology departments, utilizing advanced mathematical modeling of brain activity to simulate seizure susceptibility from standard EEG recordings. Unlike traditional methods that rely on capturing a physical seizure event, the Neuronostics architecture analyzes inter-ictal (between-seizure) data to identify hidden signatures of hyperexcitability. This technical approach addresses the high rate of misdiagnosis in epilepsy (estimated at 20-30%) and significantly reduces the time to treatment. The platform is built on a secure, cloud-native infrastructure that integrates with hospital PACS and Electronic Health Records (EHR) using FHIR/HL7 standards, enabling neurologists to generate objective seizure-risk scores. As a Lead AI Solutions Architect would note, the system's competitive advantage lies in its proprietary dynamical systems theory application, which treats the brain as a complex system rather than relying purely on heuristic-based pattern matching common in standard machine learning models.